Nurses need to know how to assess a patient’s risk of TLS and the treatment goals for successful management.
0.75 CE for NursesThe integration of billing procedures into medical records introduces the need for nurses to understand billing systems and medical payors.
0.75 CE for NursesThe issue of cancer care disparity is complex, as it is both a medical and a socioeconomic issue. Socioeconomic factors are the most universal contributors.
0.50 CE for NursesThe role of B cells in GVHD is prompting research on the effectiveness of rituximab for this common adverse effect of allogeneic hematopoietic stem cell transplantation.
0.90 CE for NursesA suspicious nodule in the right upper lung lobe is identified in a 68-year-old African-American man with a 25 pack-year smoking history but who presents with no pulmonary symptoms, apart from mild dyspnea.
0.50 AMA PRA Category 1 Credit(s)TMA stage IV adenocarcinoma of the lung is diagnosed in a 68-year-old woman who, upon routine genotyping, shows epidermal growth factor receptor and KRAS wild-type mutations.
0.50 AMA PRA Category 1 Credit(s)TMNational cancer-control programs should give high priority to pain relief and palliative care, especially in developing countries where cure of the majority of cancer patients is likely to remain beyond reach.
0.50 AMA PRA Category 1 Credit(s)TMSigns and symptoms of venous thromboembolism in oncology patients should be heeded with prompt therapeutic and mechanical interventions.
1.25 CE for NursesThis activity will allow these healthcare professionals to make the most up-to-date—and most appropriate—therapeutic decisions for their patients.
1.00 AMA PRA Category 1 Credit(s)TMTriple therapy with bendamustine, bortezomib and dexamethasone (BBD) results in a high overall response rate and good progression-free survival (PFS), in patients with relapsed/refractory multiple myeloma.
0.50 AMA PRA Category 1 Credit(s)TMThe oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has demonstrated what has been characterized as an unprecedented single agent overall response rate (ORR) in patients with relapsed or refractory mantle cell lymphoma (MCL).
0.50 AMA PRA Category 1 Credit(s)TMBendamustine plus rituximab is a promising first-line therapy for mucosa-associated lymphoid tissue (MALT) lymphoma.
0.50 AMA PRA Category 1 Credit(s)TMThe pan-BCR-ABL inhibitor ponatinib has demonstrated substantial activity and is generally well tolerated in heavily pretreated patients with resistant or refractory chronic myeloid leukemia (CML) in the advanced and chronic phases.
0.50 AMA PRA Category 1 Credit(s)TMA 60-year-old African-American woman with stage IV non-small-cell lung cancer who subsequently develops an increase in left lung mass, progressive osseous metastases, and new right lung nodules following a treatment regimen consisting of paclitaxel, carboplatin, and denosumab. What are her options for second line therapy? Dr. David Ettinger, of Johns ...
0.50 AMA PRA Category 1 Credit(s)TMThe case centers on the evaluation of the patient for systemic treatment for potential metastatic disease, the importance of molecular testing, the goals of therapy, and appropriate therapeutic interventions for a woman who did not receive a timely diagnosis.
0.50 AMA PRA Category 1 Credit(s)TMThis activity will trace the evolution and breakthroughs in various biomarker, personalized, and translational cancer research throughout 2013. It is important to carefully apply the evidence found in a way that is relevant for the community oncology setting.
1.25 AMA PRA Category 1 Credit(s)TMEmerging clinical trials data on three new treatment modalities, including abiraterone acetate, the androgen receptor-signaling inhibitor enzalutamide, and alpha pharmaceutical alpharadin, have shown prolong overall survival in castration-resistant prostate cancer (CRPC), pain reduction, and improvements in quality of life.
0.50 AMA PRA Category 1 Credit(s)TMThe theory that boosting the immune system could eradicate established tumors has existed for decades, but without clinical support.However, that premise has been partially vindicated by the success of the immunotherapy agent ipilimumab in treating metastatic melanoma.
0.50 AMA PRA Category 1 Credit(s)TMCabozantinib has an acceptable toxicity and tolerability profile at a daily dose of 40 mg/day, provides substantial pain relief, and produces a measurable bone-scan response in heavily pretreated metastatic castrate-resistant prostate cancer (CRPC) patients
0.50 AMA PRA Category 1 Credit(s)TMAs recently as 2011, treatment options for metastatic melanoma were primarily palliative, with minimal to no effect on survival rates . However, recent advances in our understanding of BRAF mutation and other genetic drivers of melanoma have led to the development of targeted therapies that have confirmed that metastatic melanoma ...
0.50 AMA PRA Category 1 Credit(s)TMNon-small-cell lung cancer (NSCLC) patients with both KRAS and P53 gene mutations may have worse outcomes following adjuvant treatment with platinum-based chemotherapy than those with neither mutation.
0.50 AMA PRA Category 1 Credit(s)TMThe main types of leukemia that affect most patients with the disease are classified by four characteristics: acute vs chronic and myeloid vs lymphoid. Each type of leukemia and its treatment has unique symptoms and risks. Oncology nurses should be able to distinguish these symptoms and educate patients appropriately.
0.75 CE for NursesAdding bortezomib to thalidomide maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) significantly prolongs progression-free survival (PFS) when compared with thalidomide alone or with single-agent alfa2-interferon (alfa2-IFN).
0.50 AMA PRA Category 1 Credit(s)TMPomalidomide plus low-dose dexamethasone significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma (MM) versus high-dose dexamethasone alone, and, therefore, should be considered a new treatment option for patients who have exhausted lenalidomide and bortezomib.
0.50 AMA PRA Category 1 Credit(s)TMThe pan-BCR-ABL inhibitor ponatinib has demonstrated substantial activity and is generally well tolerated in heavily pretreated patients with resistant or refractory chronic myeloid leukemia (CML) in the advanced and chronic phases.
0.50 AMA PRA Category 1 Credit(s)TMThe combination of rituximab and bendamustine showed significantly higher rates of complete response (CR) vs rituximab-chlorambucil among patients with chronic lymphocytic leukemia (CLL) ineligible for a fludarabine-containing standard-of-care regimen.
0.50 AMA PRA Category 1 Credit(s)TMQuizartinib (AC220) is a promising treatment for relapsed or refractory acute myeloid leukemia (AML) in patients positive for FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD[+]).
0.50 AMA PRA Category 1 Credit(s)TMThe mammalian target of rapamycin (mTOR), arguably the most frequently mutated pathway in all of breast cancer, is the target for a vast number of clinical trials of agents designed to inhibit tumor activity including estrogen receptor-positive and HER2-negative diseases, and other malignancies.
0.50 AMA PRA Category 1 Credit(s)TMAs a better understanding of the biologic subtypes of breast cancer continue to play an increasingly important role in therapeutic decision-making.
0.50 AMA PRA Category 1 Credit(s)TMThe expansion of human epidermal growth factor receptor 2 (HER2)-directed therapy in earlier stages, the continuation of HER2-directed therapy after disease progression, and the use of combined targeted approaches are the common and uniting themes that have led to the major advances in the treatment of HER2-positive metastatic breast cancer.
0.50 AMA PRA Category 1 Credit(s)TMResults from an international, randomized study showed that extending the duration of adjuvant tamoxifen treatment to 10 years in women with estrogen receptor-positive breast cancer appears to reduce the risk for late tumor recurrence.
0.50 AMA PRA Category 1 Credit(s)TMDespite substantial progress in the management of advanced breast cancer (ABC) over the past decade, the median overall survival for women with ABC is still between 2 and 3 years.
0.50 AMA PRA Category 1 Credit(s)TMIn light of evidence that patients with triple-negative breast cancer, though initially responsive to chemotherapy, tend to quickly relapse, leading to a poor prognosis, there is a urgent need to understand the molecular basis of this disease.
0.50 AMA PRA Category 1 Credit(s)TMSequencing technology, the deciphering of DNA sequences and characterizing somatic mutations in cancer genomes, is now at the forefront of a newer strategy for better understanding and treating breast cancer and will be used repeatedly for breast cancer prognosis and diagnosis prediction.
0.50 AMA PRA Category 1 Credit(s)TMCreating an environment that is conducive for cancer survivors to discuss these and other concerns may well be the first step on the road to navigating obstacles.
0.50 AMA PRA Category 1 Credit(s)TMThis activity is taken from the February 2013 issue of JAAPA. It includes the CME articles "Chronic myeloid leukemia: Advances in diagnosis and management" and "Postpartum depression: Symptoms, diagnosis, and treatment approaches." Please note that both topics are included in the post-test.
1.00 AAPA Category I CME CreditBased on data regarding the risks associated with erythropoietinstimulating agents (ESAs), the FDA recommended a Risk Evaluation Mitigation Strategy (REMS) program for these agents. Nurses play an important role in ensuring that prescribed treatment plans are appropriate for a particular patient (eg, laboratory parameters are appropriate).
0.75 CE for Nurses
This module reviews all topics on the NCCPA examination blueprint relating to the Infectious Disease, Endocrine, Hematologic, and Dermatologic systems, and aims to enhance performance on the PANCE and PANRE for these sections.
5.50 AAPA Category I CME CreditThe most common complications associated with VADs are catheter-related infections and occlusions. Diagnosis and management of these complications, however, are not standardized and remain a challenge to nurses.
1.50 CE for NursesCompared with solvent-based paclitaxel, albumin-bound nab-paclitaxel exhibits 10-fold higher mean Cmax of free paclitaxel and preclinical models have shown higher drug concentration to tumors and enhanced cell transport.
0.50 AMA PRA Category 1 Credit(s)TMUpdated results from the ongoing global phase 2 study with crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC).
0.50 AMA PRA Category 1 Credit(s)TMRapidly evolving sequencing technologies characterizing the cancer genome have shown that not only do germline and somatic alterations in DNA mediate genesis and progression of cancer, but they also are clinically important as diagnostic markers and therapeutic targets.
0.50 AMA PRA Category 1 Credit(s)TMLUX-Lung 3, the largest prospective trial in patients with EGFR-mutation–positive advanced adenocarcinoma of the lung and the first pivotal trial in Asian and non-Asian patients with EGFR mutations, found afatinib significantly prolonged progression-free survival (PFS).
0.50 AMA PRA Category 1 Credit(s)TMLow-dose CT screening may benefit individuals at an increased risk for lung cancer; however, uncertainty exists about the potential harms of screening and the generalizability of the results.
0.50 AMA PRA Category 1 Credit(s)TMHigh-dose radiation therapy does not improve overall survival (OS) versus a standard radiotherapy dose in patients with locally advanced non−small-cell lung cancer (NSCLC); however, intensity modulated radiotherapy (IMRT) may lead to a better OS rate in patients with stage III disease.
0.50 AMA PRA Category 1 Credit(s)TMKRAS is the most common driver mutation observed in lung cancer. Discovered in the 1980s, KRAS mutations were initially stereotyped in the literature as occurring primarily in heavy smokers.
0.50 AMA PRA Category 1 Credit(s)TMPatients and their families often have a limited understanding of their illness and an inaccurate view of their prognosis; and patients face difficult decisions about their cancer treatment and end-of-life care. Yet, with increasing use of personalized therapy, survival can only increase.
0.50 AMA PRA Category 1 Credit(s)TMThis webcast educates clinicians regarding the biochemical pathways that lead to trastuzumab resistance in HER2-positive tumors and current options to overcome such resistance or other options to increase progression-free survival.
1.00 AMA PRA Category 1 Credit(s)TMTriple-negative breast cancer (TNBC) is highly resistant to treatment and remains the most challenging subtype of cancer to treat, particularly once it has progressed.
1.00 AMA PRA Category 1 Credit(s)TMThis case of a 46-year-old premenopausal African American woman outlines therapeutic considerations for adjuvant therapy of metastatic estrogen-receptor negative (ER-), progesterone-receptor negative (PR-), HER2-negative, or triple-negative breast cancer (TNBC).
0.75 AMA PRA Category 1 Credit(s)TMThis case takes a detailed look at a 71-year-old white female who had been previously diagnosed with a stage-2 invasive hormone-receptor (HR) negative, HER2-positive ductal carcinoma along with 4 of 9 axillary lymph nodes involved with metastatic disease.
0.75 AMA PRA Category 1 Credit(s)TMThis case focuses on a 64-year-old Hispanic female with type 2 diabetes mellitus who is diagnosed with estrogen-receptor (ER) and progesterone-receptor (PR) positive breast cancer.
0.75 AMA PRA Category 1 Credit(s)TMFrom the September/October 2011 Oncology Nurse Advisor: This activity is designed to give an overview of the causes of CIPN, its symptoms, and possible prevention and treatment strategies.
1.25 CE for NursesThe most appropriate management options for women with endocrine-resistant breast cancer are unclear, so it’s critical for clinicians to remain informed about the most clinically relevant outcomes of trials presented/published in the past 18 months.
1.00 AMA PRA Category 1 Credit(s)TMThe potent, oral, pan-BCR-ABL inhibitor ponatinib has demonstrated robust antileukemic activity in a heavily pretreated population of patients with chronic myelogenous leukemia or Ph positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or nilotinib or have the T315I mutation.
0.50 AMA PRA Category 1 Credit(s)TMA light smoker presents to his primary care physician with a few weeks’ history of a cough and is ultimately diagnosed with non-small cell lung cancer. Based on a genetic alteration in his tumor, this man may be a candidate for molecularly targeted non-small cell lung cancer therapy.
1.00 AMA PRA Category 1 Credit(s)TMThis fourth and final i-newsletter issue in this series focuses on promising emerging oncogenes and targeted therapies.
0.50 AMA PRA Category 1 Credit(s)TMThe first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC).
0.25 AMA PRA Category 1 Credit(s)TMPatients with metastatic cancer who received early palliative care intervention had immediate improvement in satisfaction with care and later improvement in quality of life (QOL) and symptom control compared with standard care.
0.50 AMA PRA Category 1 Credit(s)TMPomalidomide in combination with low-dose dexamethasone has shown a 30% overall response rate in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both, including those with prior transplant.
0.50 AMA PRA Category 1 Credit(s)TMThe combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses.
0.50 AMA PRA Category 1 Credit(s)TMPatients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone.
0.50 AMA PRA Category 1 Credit(s)TMContinuous androgen deprivation may be a preferred treatment option for hormone-sensitive metastatic prostate cancer in men with minimal disease spread, according to results of a long-term international phase 3 trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.
0.50 AMA PRA Category 1 Credit(s)TMFrom the August 2012 issue of The Clinical Advisor: Infections, tumors, and lumps affecting the scrotal content. A lump, enlarging scrotum or pain can conjure up images of testicular cancer, but other conditions involving the scrotal content are possible.
0.50 AAPA Category I CME CreditThe development of screening strategies that allow for early diagnosis and comprehension of tumor biology will likely improve outcomes in these patients, as will utilization of investigational agents that are associated with positive patient response.
1.00 AMA PRA Category 1 Credit(s)TMWhile there is no cure for most patients with glioblastoma multiforme (GBM), emerging evidence from recent research offers healthcare providers opportunities to prolong survival and improve patients’ quality of life.
1.25 AMA PRA Category 1 Credit(s)TMThis activity uses an online, case-based approach to discuss strategies for the optimal management of cancer pain for both the oncologist and primary care clinician.
1.75 AMA PRA Category 1 Credit(s)TMFrom the July/August 2011 Oncology Nurse Advisor: Knowledge of the risk factors for ototoxicity and understanding the appropriate interventions can help promote continued social and emotional development in young patients.
1.00 CE for NursesThe CTCA REVIEW online webcasts highlight cutting-edge research and clinical studies presented during recent American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings.
1.50 AMA PRA Category 1 Credit(s)TMThe CTCA REVIEW online webcasts highlight cutting-edge research and clinical studies presented during recent American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings.
1.50 AMA PRA Category 1 Credit(s)TMThis activity will provide education on specific unmet needs and clinical gaps in the area of renal cell cancer.
0.75 AMA PRA Category 1 Credit(s)TMThe experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC).
0.50 AMA PRA Category 1 Credit(s)TMTaxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer.
0.50 AMA PRA Category 1 Credit(s)TMAdjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival.
0.50 AMA PRA Category 1 Credit(s)TMSeveral analyses of the international randomized phase 3 Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) plus exemestane versus exemestane alone for the treatment of postmenopausal women.
0.50 AMA PRA Category 1 Credit(s)TMThe goal of this continuing medical education activity is to increase knowledge and competency among hematology/oncology clinicians regarding best practices in the management of AML.
1.00 AMA PRA Category 1 Credit(s)TMAssessing and incorporating new data from the ASCO meeting will assist oncologists in individualizing therapy for their patients with NSCLC and achieving these goals.
1.00 AMA PRA Category 1 Credit(s)TMThis third i-Newsletter issue focuses on the evolving use of bevacizumab.
0.50 AMA PRA Category 1 Credit(s)TMFrom the June 2012 issue of The Clinical Advisor: Oral Involvement of Systemic Diseases. Oral manifestations are often an early signal of systemic disease, so recognizing them can point the way to a prompt diagnosis.
0.50 AAPA Category I CME CreditIndividuals at high risk of developing lung cancer should undergo annual screening with low-dose computed tomography (CT).
0.50 AMA PRA Category 1 Credit(s)TMStudies assessing the benefit of prostate-specific antigen (PSA) screening to reduce mortality for prostate cancer have yielded mixed results, and so for now, physicians and patients are left to debate this issue on an individual basis.
0.50 AMA PRA Category 1 Credit(s)TMAlthough the use of targeted therapies has dramatically improved survival for women with breast cancer, the role of such agents, including exemestane and the trastuzumab, must be based on an informed discussion on the benefits and risk between patients and their physicians.
0.50 AMA PRA Category 1 Credit(s)TMFrom the May/June 2011 Oncology Nurse Advisor: Management and prognosis for patients with non-Hodgkin lymphoma depend on identifying the disease type. This review discusses the diagnoses and optimal treatments.
1.00 CE for NursesThis second i-Newsletter issue focuses on defining and treating NSCLC patients with EGFR-TKI acquired resistance.
0.50 AMA PRA Category 1 Credit(s)TMDrugs reviewed in this edition include Ruxolitinib (Jakafi), Aflibercept (Eylea), Ingenol mebutate (Picato gel), Exenatide extended-release (Bydureon).
0.75 AMA PRA Category 1 Credit(s)TMThis case reviews management of urogenital atrophy in a woman whose oncologist switched her from tamoxifen to an aromatase inhibitor.
0.75 AMA PRA Category 1 Credit(s)TMDrugs reviewed in this edition include rivaroxaban (Xarelto), cetuximab (Erbitux), linagliptin and metformin hydrochloride (Jentadueto), fentanyl nasal spray (Lazanda).
0.75 AMA PRA Category 1 Credit(s)TMThis activity examines diagnostic and prognostic criteria, novel agents and combinations of therapy, management of treatment-related toxicities, and education and counseling of patients with multiple myeloma.
0.50 CE for NursesFrom the March/April 2011 Oncology Nurse Advisor:Hereditary nonpolyposis colorectal cancer is caused by an inherited genetic mutation. This review explains how to screen and counsel patients at risk.
0.75 CE for NursesThis newsletter issue focuses on steps to identify and treat NSCLC who test positive for ALK rearrangement.
0.50 AMA PRA Category 1 Credit(s)TMIt is imperative that practioners be knowledgeable about new drugs and dosage formulations introduced to the market. Participants learn about the indications, dosing, adverse effects, drug interactions, and appropriate use of new analgesics and other medications used for palliative care in this fast paced discussion.
1.00 AMA PRA Category 1 Credit(s)TMThis panel presents the conflict that exists in the treatment of chronic pain patients. Patients in pain clinics are frequently required to submit to a range of procedures such as pill counts, urine screens, and similar demoralizing testing, in a very paternalistic setting.
1.25 AMA PRA Category 1 Credit(s)TMThis master class addresses the numerous issues (psychiatric and social needs) and treatment options for cancer survivors who experience chronic pain.
1.75 AMA PRA Category 1 Credit(s)TMThis session discusses the history and development of RES up to the recent failed submission by the FDA of a class-wide REMS
1.25 AMA PRA Category 1 Credit(s)TMDrugs reviewed in this edition include telaprevir (Incivek), sitagliptin and simvastatin (Juvisync), linagliptin (Tradjenta), vemurafenib (Zelboraf).
0.75 AMA PRA Category 1 Credit(s)TMThis program provides participants with an update on therapeutic strategies that are currently being evaluated in National Cancer Institute-sponsored clinical trials performed by the New York Cancer Consortium and other groups.
1.00 AMA PRA Category 1 Credit(s)TMThis activity's goal is to increase knowledge and competency among clinicians regarding best practices in the management of acute myeloid leukemia.
1.00 AMA PRA Category 1 Credit(s)TMA 54-year-old Caucasian male with a history of multiple myeloma post–autologous SCT presents with increasing fatigue and progressive anemia complains of fatigue to his hematologist.
1.00 AMA PRA Category 1 Credit(s)TMThis activity is taken from the November 2011 issue of JAAPA. It includes the CME articles “Hepatorenal syndrome: Progressive renal failure in patients with cirrhosis" and "Oral anticoagulation: A review of the current and emerging therapies." Please note that both topics are included in the post-test.
1.00 AAPA Category I CME CreditEducation is needed around the safe use of opioid analgesics and more specifically the IR fentanyl medications for BTCP. This educational program is specifically designed to support this objective.
0.75 AMA PRA Category 1 Credit(s)TM